Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancer

被引:0
|
作者
Bidakhvidi, Niloefar Ahmadi [1 ,2 ]
Gevaert, Thomas [3 ]
De Schepper, Maxim [4 ]
Baldewijns, Marcella [4 ]
Havinga, Enrique [5 ]
Deckers, Wies [1 ]
Laenen, Annouschka [6 ]
Devos, Gaetan [3 ,7 ]
Giesen, Alexander [3 ,7 ]
Joniau, Steven [3 ,7 ]
Koole, Michel [1 ,2 ]
Everaerts, Wouter [7 ,8 ]
Deroose, Christophe M. [1 ,2 ]
Goffin, Karolien [1 ,2 ]
机构
[1] Univ Hosp Leuven, Nucl Med, Leuven, Belgium
[2] Katholieke Univ Leuven, Dept Imaging & Pathol, Nucl Med & Mol Imaging, Leuven, Belgium
[3] Katholieke Univ Leuven, Dept Dev & Regenerat, Urogenital Abdominal & Plast Surg, Leuven, Belgium
[4] Univ Hosp Leuven, Pathol, Leuven, Belgium
[5] Univ Hosp Leuven, Radiol, Leuven, Belgium
[6] Interuniv Inst Biostat & Stat Bioinformat, Leuven, Belgium
[7] Univ Hosp Leuven, Urol, Leuven, Belgium
[8] Katholieke Univ Leuven, Lab Ion Channel Res, Dept Cellular & Mol Med, Leuven, Belgium
关键词
PSMA PET; PSMA immunohistochemistry; PET/MR; Parametric PET; Primary prostate cancer; IMMUNOREACTIVE SCORE; PET/CT; RECEPTORS; TISSUE; IRS;
D O I
10.1007/s00259-024-06903-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Quantification of PSMA expression via PSMA PET is well-established, however quantification of PSMA via immunohistochemistry (IHC) is not standardized. Our aim was to determine the most optimal PSMA IHC scoring system to quantify PSMA expression with PSMA PET as reference standard. Methods Primary intermediate- and high-risk prostate cancer patients received an [F-18]PSMA-1007 PET/MRI followed by radical prostatectomy. SUVmax, SUVmean and K-i of the prostate tumor was determined. Prostate tumors were stained with anti-PSMA antibodies and scored by 2 readers via 10 IHC scoring systems: histochemical score (H-score), immunoreactivity score(predominant intensity) (IRSpredominant intensity), IRS classification(predominant intensity), IRSmean intensity, IRS classification(mean intensity), Allred score, predominant expression pattern, Shannon diversity index (SDI), percentage negatively stained cells and total percentage positively stained cells. Spearman's rank correlation coefficients (rho) were calculated between PET parameters and IHC scoring systems. Interreader agreement for the IHC scoring systems was measured by the intraclass correlation coefficient (ICC). Results Fifty tumors in 46 patients were analysed. H-score had the best correlation with SUVmax (rho 0.615 p < 0.0001) and SUVmean (rho 0.570, p < 0.0001) and the second best correlation with Ki (rho 0.411, p = 0.0030). SDI had the best correlation with Ki (rho -0.440, p = 0.0014) and the second best correlation with SUVmax (rho -0.516, p = 0.0001) and SUVmean (rho -0.490, p = 0.0003). A moderate interreader agreement was observed for H-score (ICC 0.663, 95% CI 0.495-0.797) and SDI (ICC 0.546, 95% CI 0.354-0.725). Conclusion H-score had the best correlation with PSMA PET quantification and an acceptable interreader agreement. Therefore, we deem H-score the most optimal PSMA IHC scoring system.
引用
收藏
页码:766 / 778
页数:13
相关论文
共 50 条
  • [41] Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology
    Prive, Bastiaan M.
    Israel, Bas
    Schilham, Melline G. M.
    Muselaers, Constantijn H. J.
    Zamecnik, Patrik
    Mulders, Peter F. A.
    Witjes, J. Alfred
    Sedelaar, Michiel
    Mehra, Niven
    Verzijlbergen, Fred
    Janssen, Marcel J. R.
    Gotthardt, Martin
    Barentsz, Jelle O.
    van Oort, Inge M.
    Nagarajah, James
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (02) : 423 - 430
  • [42] Simplified Semi-Quantification of [18F]PSMA-1007 Uptake in Treatment-Naive Primary Prostate Cancer
    Bidakhvidi, N. Ahmadi
    Koole, M.
    Everaerts, W.
    Joniau, S.
    Deroose, C. M.
    Goffin, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S505 - S506
  • [43] High detection sensitivity in [18F]PSMA-1007 PET: initial experience focusing on biochemical recurrence in prostate cancer patients
    Watabe, T.
    Uemura, M.
    Soeda, F.
    Naka, S.
    Sasaki, H.
    Kamiya, T.
    Shimosegawa, E.
    Kato, H.
    Nonomura, N.
    Giesel, F. L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S365 - S366
  • [44] Assessing the accuracy of [18F]PSMA-1007 PET/CT for primary staging in prostate cancer with extended lymph node dissection as reference method
    Hvittfeldt, E.
    Ingvar, J.
    Tragardh, E.
    Simoulis, A.
    Bjartell, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S482 - S482
  • [45] Routine Production of [18F] PSMA-1007 and First Clinical Experience in Staging of Prostate Cancer Patients
    Kramer, Vasko
    Fernandez, Rene
    Sandoval, Maria-Paz
    Gameiro, Cristiana
    Goblet, David
    Mueller, Marco
    Zerges, Anna-Maria
    Martin, Rene
    Sandoval, Camilo
    Amaral, Horacio
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [46] High detection rate in [18F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients
    Watabe, Tadashi
    Uemura, Motohide
    Soeda, Fumihiko
    Naka, Sadahiro
    Ujike, Takeshi
    Hatano, Koji
    Sasaki, Hidetaka
    Kamiya, Takashi
    Shimosegawa, Eku
    Kato, Hiroki
    Cardinale, Jens
    Tateishi, Ukihide
    Nonomura, Norio
    Giesel, Frederik L.
    ANNALS OF NUCLEAR MEDICINE, 2021, 35 (04) : 523 - 528
  • [47] Added Value of [18F]PSMA-1007 PET/CT and PET/MRI in Patients With Biochemically Recurrent Prostate Cancer: Impact on Detection Rates and Clinical Management
    Abrahamsen, Bendik S.
    Tandstad, Torgrim
    Aksnessaether, Bjorg Y.
    Bogsrud, Trond V.
    Castillejo, Miguel
    Hernes, Eivor
    Johansen, Hakon
    Keil, Thomas M. I.
    Knudtsen, Ingerid S.
    Langorgen, Sverre
    Selnaes, Kirsten M.
    Bathen, Tone F.
    Elschot, Mattijs
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2025, 61 (01) : 466 - 477
  • [48] Enhancing the diagnostic capacity of [18F]PSMA-1007 PET/MRI in primary prostate cancer staging with artificial intelligence and semi-quantitative DCE: an exploratory study
    Glemser, Philip Alexander
    Freitag, Martin
    Kovacs, Balint
    Netzer, Nils
    Dimitrakopoulou-Strauss, Antonia
    Haberkorn, Uwe
    Maier-Hein, Klaus
    Schwab, Constantin
    Duensing, Stefan
    Beuthien-Baumann, Bettina
    Schlemmer, Heinz-Peter
    Bonekamp, David
    Giesel, Frederik
    Sachpekidis, Christos
    EJNMMI REPORTS, 2024, 8 (01)
  • [49] Head-to-Head Comparison of [18F]PSMA-1007 and [18F]FDG PET/CT in Patients with Triple-Negative Breast Cancer
    Andryszak, Natalia
    Swiniuch, Daria
    Wojcik, Elzbieta
    Ramlau, Rodryg
    Ruchala, Marek
    Czepczynski, Rafal
    CANCERS, 2024, 16 (03)
  • [50] Head-to-Head Comparison of [18F]PSMA-1007 and [18F] FDG PET/CT in Patients with Triple-Negative Breast Cancer
    Andryszak, N.
    Swiniuch, D.
    Wojcik, E.
    Ramlau, R.
    Ruchala, M.
    Czepczynski, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S18 - S19